2.90

0.68% -0.02

After Hours: 2.90

Xeris Biopharma Holdings Inc (XERS)

Overview News Price History Option Chain Financials Discussions Forecast

Xeris Biopharma Holdings Inc stock is traded at $2.90, with a volume of 1.41M. It is down -0.68% in the last 24 hours and down -5.23% over the past month. Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Previous Close:

$2.92

Open:

$2.91

24h Volume:

1.41M

Relative Volume:

0.90

Market Cap:

$432.34M

Revenue:

$181.41M

Net Income/Loss:

$-59.56M

P/E Ratio:

-5.5769

EPS:

-0.52

Net Cash Flow:

$-38.83M

1W Performance:

-11.59%

1M Performance:

-5.23%

6M Performance:

+46.46%

1Y Performance:

+63.84%

1-Day Range:

$2.82

$2.93

1-Week Range:

$2.82

$3.325

52-Week Range:

$1.69

$3.64

Xeris Biopharma Holdings Inc Stock (XERS) Company Profile

Name

Xeris Biopharma Holdings Inc

Sector

Healthcare (1196)

Industry

Biotechnology (683)

Phone

844-445-5704

Address

1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL

Employee

377

Twitter

@XerisPharma

Next Earnings Date

2024-12-08

Latest SEC Filings

XERS's Discussions on Twitter

Compare XERS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XERS	2.90	432.34M	181.41M	-59.56M	-38.83M	-0.52
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-21-22	Initiated	Jefferies	Buy
Apr-28-22	Initiated	Craig Hallum	Buy
Nov-17-21	Initiated	SVB Leerink	Outperform
Oct-29-21	Initiated	H.C. Wainwright	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-18-20	Initiated	Piper Sandler	Overweight
Jul-16-18	Initiated	Jefferies	Buy
Jul-16-18	Initiated	Leerink Partners	Outperform
Jul-16-18	Initiated	RBC Capital Mkts	Outperform

View All

Xeris Biopharma Holdings Inc Stock (XERS) Latest News

Nov 17, 2024

Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long - Yahoo Finance

Nov 17, 2024

Nov 16, 2024

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS): When Will It Breakeven? - Simply Wall St

Nov 16, 2024

Nov 14, 2024

HC Wainwright Forecasts Reduced Earnings for Xeris Biopharma - Defense World

Nov 14, 2024

Wealth Enhancement Advisory Services LLC Invests $35,000 in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World

Nov 14, 2024

FY2024 EPS Estimate for Xeris Biopharma Raised by Analyst - Defense World

Nov 14, 2024

Nov 13, 2024

HC Wainwright Forecasts Higher Earnings for Xeris Biopharma - MarketBeat

Nov 13, 2024

Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Neutral at Piper Sandler - Defense World

Nov 13, 2024

Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World

Nov 13, 2024

Nov 12, 2024

HC Wainwright Forecasts Weaker Earnings for Xeris Biopharma - MarketBeat

Nov 12, 2024

Nov 10, 2024

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 10, 2024

Nov 09, 2024

Earnings call: Xeris Biopharma posts record revenue in Q3 2024 - Investing.com India

Nov 09, 2024

Earnings call: Xeris Biopharma posts record revenue in Q3 2024 By Investing.com - Investing.com Nigeria

Nov 09, 2024